BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Revotar Biopharmaceuticals AG 

Neuendorfstrasse 24a

Hennigsdorf    16761  Germany
Phone: 49-3302-2025062 Fax: 49-3302-2025030


SEARCH JOBS

View Clinical Trials from BioPharm Insight




Segment
Research





 Company News
Revotar Biopharmaceuticals Receives New Composition-of-Matter Patent for Bimosiamose in the US 11/2/2011 9:29:14 AM
Revotar Biopharmaceuticals Positive Multi-Center COPD Trial with Inhaled Bimosiamose to be Presented at the European Respiratory Society Annual Congress 2011 in Amsterdam 9/21/2011 6:50:19 AM
Revotar Biopharmaceuticals Presents Significant Final Results from 4 Weeks Phase II COPD Study 5/19/2011 8:46:46 AM
Revotar Biopharmaceuticals Meets Primary Endpoint in Phase II COPD Study with Inhaled Bimosiamose 3/4/2011 7:09:27 AM
Revotar Biopharmaceuticals Starts Phase II Clinical Trial in COPD Patients with Inhaled Bimosiamose 6/10/2010 11:18:39 AM
Revotar Biopharmaceuticals Presents Positive Results In Phase IIa Ozone Study With Bimosiamose For COPD 5/18/2010 12:09:20 PM
Revotar Biopharmaceuticals Announces the Appointment of Ludwig Felber as Chief Financial Officer and Member of the Executive Board and the Election of Prof Dr Wolfgang Hartwig as New Supervisory Board Member 6/3/2009 2:37:29 PM
Revotar Biopharmaceuticals Starts Phase II Clinical Trial in Psoriasis with its Bimosiamose 5% Cream 2/2/2009 3:09:16 PM
Revotar Biopharmaceuticals Reports Positive Preclinical Data From A 4-Month Dermal Toxicity Study 10/29/2008 11:49:45 AM
Revotar Biopharmaceuticals Reports Positive Phase I Data In Psoriasis With Its Bimosiamose 5% Cream 10/13/2008 2:23:09 PM
12